NCT02943850View on ClinicalTrials.gov

CNS10-NPC-GDNF for the Treatment of ALS

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

October 18, 2019

Study Completion Date

October 18, 2019

Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIOLOGICAL

Stem cell (HPC) implantation

All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.

DEVICE

Stereotactic surgical device

A newly developed stereotactic frame is being evaluated as a part of this trial

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Cedars-Sinai Medical Center

OTHER

NCT02943850 - CNS10-NPC-GDNF for the Treatment of ALS | Biotech Hunter | Biotech Hunter